CLDX
Celldex Therapeutics, Inc. Earnings
$25.14
Earnings Summary
Revenue | $3.19Mn |
Net Profits | $-42.12Mn |
Net Profit Margins | -1319.99% |
Celldex Therapeutics, Inc.’s revenue jumped 110.35% since last year same period to $3.19Mn in the Q3 2024. On a quarterly growth basis, Celldex Therapeutics, Inc. has generated 27.74% jump in its revenue since last 3-months.
Celldex Therapeutics, Inc.’s net profit fell -10.09% since last year same period to $-42.12Mn in the Q3 2024. On a quarterly growth basis, Celldex Therapeutics, Inc. has generated -17.52% fall in its net profits since last 3-months.
Celldex Therapeutics, Inc.’s net profit margin jumped 47.66% since last year same period to -1319.99% in the Q3 2024. On a quarterly growth basis, Celldex Therapeutics, Inc. has generated 8% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Celldex Therapeutics, Inc. post its latest quarter earningsEPS Estimate Current Year | -0.69 |
Celldex Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.69.
Key Ratios
Key ratios of the Celldex Therapeutics, Inc. post its Q3 2024 earningsEarning Per Share (EPS) | -0.64 |
Celldex Therapeutics, Inc.’s earning per share (EPS) jumped 20.99% since last year same period to -0.64 in the Q3 2024. This indicates that the Celldex Therapeutics, Inc. has generated 20.99% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2024-11-06 | -0.67 | -0.64 | 4.48% |
2024-08-08 | -0.59 | -0.54 | 8.47% |
2024-05-06 | -0.69 | -0.56 | 18.84% |
₹0 US Stocks a/c Opening Fee